Biofrontera (BFRI) Debt Ratio (2021 - 2024)

Biofrontera's (BFRI) quarterly Debt Ratio came in at 0.01 in Q2 2024, down 85.68% quarter-over-quarter from 0.1 in Q1 2024.

Biofrontera (BFRI) Debt Ratio (2021 - 2024) Analysis & Trends

Biofrontera's Debt Ratio history runs 4 years deep, the most recent figure standing at 0.01 for Q2 2024.

  • On a quarterly basis, Debt Ratio changed N/A year-over-year to 0.01 in Q2 2024; TTM through Jun 2024 was 0.01, a N/A change from a year earlier, with the FY2023 full-year figure at 0.14, up 2.45% from the prior year.
  • Debt Ratio declined to 0.01 in Q2 2024 per BFRI's latest filing, from 0.1 in the prior quarter.
  • Across five years, Debt Ratio topped out at 405.25 in Q4 2021 and bottomed at 0.01 in Q2 2024.
  • The 4-year median for Debt Ratio is 0.12 (2022), against an average of 50.74.
  • Across the five-year window, Debt Ratio sank 99.97% in 2022 and advanced 2.45% in 2023, its largest moves.
  • Year by year, Debt Ratio stood at 405.25 in 2021, then sank by 99.97% to 0.14 in 2022, then advanced by 2.45% to 0.14 in 2023, then slumped by 90.18% to 0.01 in 2024.
  • Per Business Quant, the three latest BFRI Debt Ratio figures stand at 0.01 (Q2 2024), 0.1 (Q1 2024), and 0.14 (Q4 2023).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - 0.26
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn 0.42
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn 0.60
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn 0.29
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn -
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - 0.10
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn 0.39
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn -
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn 0.29
10 Biofrontera 12.70 Mn 6.29 Mn 14.09 Mn -

Historic Data

Download Data
DateValue
Jun 30, 2024 0.01
Mar 31, 2024 0.10
Dec 31, 2023 0.14
Sep 30, 2023 0.05
Mar 31, 2023 0.17
Dec 31, 2022 0.14
Sep 30, 2022 0.06
Dec 31, 2021 405.25